This content is machine translated Advanced high-grade serous ovarian cancer. HRD+ tumors: first PARP inhibitor approved for first-line maintenance therapy As the first and only PARP inhibitor, olaparib was recently approved by swissmedic for first-line maintenance therapy in patients with advanced, HRD-positive ovarian cancer. The addition of olaparib to bevacizumab resulted…
View Post 8 min This content is machine translated Plasma cell myeloma Preferences in myeloma treatment in Switzerland 2018 With the approval of several new drugs, the treatment spectrum for second-line therapy of plasma cell myeloma has been expanded. In parallel, established treatment concepts, predominantly in first-line treatment, were…
View Post 6 min This content is machine translated ESMO 2018 in Munich Quantum leap in ovarian cancer? The SOLO-1 trial was one of the “hot” topics at this year’s ESMO. A PFS improvement of 70% with good tolerance and efficacy not only in recurrences suggest a relevant…
View Post 7 min This content is machine translated Therapy for initial diagnosis of multiple myeloma Treatment protocols in the age of modern substances We are in the era of new efficient compounds against multiple myeloma. Nevertheless, high-dose chemotherapy followed by autologous stem cell transplantation remains an essential part of the first-line treatment of…
View Post 3 min This content is machine translated Follicular lymphoma Rituximab in maintenance monotherapy. A study presented at ASH 2013 in New Orleans examined the role of rituximab in maintenance therapy in patients with follicular lymphoma. The study showed that the drug, when applied…
View Post 6 min This content is machine translated Non-Hodgkin's lymphoma and myelodysplastic syndrome What are the benefits of lenalidomide and pomalidomide? At the ASH Congress in New Orleans, the focus was on the efficacy and safety of lenalidomide plus low-dose dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.…
View Post 6 min This content is machine translated Chronic lymphocytic leukemia and non-Hodgkin's lymphoma Updates on the active ingredients GA101 and rituximab Three studies on chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma were discussed at the ASH in New Orleans: One was an update on the stage 1 analysis of the CLL11…
View Post 12 min This content is machine translated Non-small cell lung cancer Individualized, palliative first-line therapy is possible Therapy for non-small cell lung cancer is individualized and based on tumor stage, histology, and predictive molecular markers, taking into account the patient profile. To maximize the therapeutic outcome for…
